Please wait a minute...
European Journal of Gynaecological Oncology  2019, Vol. 40 Issue (6): 1000-1005    DOI: 10.12892/ejgo5160.2019
Original Research Previous articles | Next articles
Prognostic factors in endometrial cancer Stages III and IV: a single academic institution experience of 49 patients
V. Loizzi1, V. Del Vecchio1, *(), E. Pisani1, G. Ranieri3, L. Resta2, E. Cicinelli1, G. Cormio1, 3
1Department of Biomedical Science and Human Oncology, Obstetrics and Gynecology Unit, University of Bari, Italy
2Department of Pathology, University of Bari, Italy
3Istituto Tumori Giovanni Paolo II I.R.C.C.S., Bari, Italy
Download:  PDF(481KB)  ( 153 ) Full text   ( 4 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Background: To evaluate the clinical and pathologic factors associated with survival in patients with advanced staged endometrial carcinoma. Matreials and Methods: Between 2005 and 2017 all patients with endometrial carcinoma type I were identified from tumor registry databases at this Academic hospital. The impact of clinical and pathologic risk factors on the survival of patients with endometrial carcinoma was evaluated using Kaplan-Meier life table analyses and log-rank tests. Results: Forty-nine patients with advanced endometrial cancer were collected. The median progression-free survival (PFS) for all patients was 42 months whereas the median overall survival (OS) was 69 months for all patients. Univariate analysis was extended to all prognostic factors for all stages showed as statistically significant positive cytology and cervical invasion, whereas for Stage III only cervical invasion. For Stage IIIA the prognostic factors statistically significant were cervical invasion and lymphovascular space invasion (LVSI). Furthermore, prognosis was worse in tumors belonging to Stage IV with positive cytology. Conclusion: Prognostic factors related to a lower survival rate in advanced stages of endometrial cancer are represented by cervical invasion, LVSI, and positive peritoneal cytology. These factors with respect to LVSI and positive peritoneal cytology should be included in FIGO 2009 surgical staging system because associated to a poor prognosis.

Key words:  Prognostic Factors      Uterine carcinoma      Endometrial carcinoma     
Published:  10 December 2019     
*Corresponding Author(s):  V. DEL VECCHIO     E-mail:  vittoria.delvecchiomd@gmail.com

Cite this article: 

V. Loizzi, V. Del Vecchio, E. Pisani, G. Ranieri, L. Resta, E. Cicinelli, G. Cormio. Prognostic factors in endometrial cancer Stages III and IV: a single academic institution experience of 49 patients. European Journal of Gynaecological Oncology, 2019, 40(6): 1000-1005.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo5160.2019     OR     https://ejgo.imrpress.com/EN/Y2019/V40/I6/1000

[1] T. Sakamoto, M. Miyamoto, T. Kono, H. Tsuada, H. Matsuura, T. Aoyama, M. Takano, K. Furuya. Endometrial dedifferentiated carcinoma: a case report. Pathological review at a single institution and systematic review of published literature[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 163-166.
[2] M. Pakiž, A. Dovnik, B. Crnobrnja, P. Zola. Increased incidence of advanced stage endometrial cancer: a retrospective analysis of different clinical approaches and tumour biology[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 246-251.
[3] H. Wang, Y. Peng, Y. Liu, X. Li, A. Gu, H. He, M. Feng, D. Mao, L. Guo. Expression of HIWI in endometrial carcinoma tissues and its clinical significance[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 256-259.
[4] A. R. H. Ahmed, R. A. Bakheet, W. Abdelmohsen, M. Mohammed, M. A. Adly. Balance of glandular and stromal Bcl2/Bax expression in pre-neoplastic and neoplastic endometrial tissues[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 265-272.
[5] X.Z. Cheng, Z. Zhou, M.Y. Yang, Y.L. Cai, F. Deng, X.X. Chen. Prognostic factors for types I and II epithelial ovarian cancer in the elderly[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 7-15.
[6] R. Pereira Souza, G. Pinheiro Soares, L. Valente Lage, G. Baiocchi, A.A.B.A. da Costa, M. del Pilar Eestevez Diz. Platinum rechallenge in second-line treatment for endometrial carcinoma[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 963-969.
[7] A. Jaishuen, N. Boonkhum, J. Petsuksiri, N. Jareemit, P. Srichaikul, S. Therasakvichya. Outcomes of treatment for Stage III endometrial carcinoma patients[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 803-809.
[8] H. Ibrahim, K. Dresser, K. M. Cornejo. Loss of 5-hydroxymethylcytosine (5-hmC) expression in endometrioid type endometrial carcinoma[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 846-848.
[9] Lan Zhong, Feng Deng, Xingsheng Shu, Zhilan Peng. P53 overexpression predicts unfavorable prognosis of low risk endometrial carcinoma[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 463-467.
[10] A. Markowska, M. Bocianowska, J. Markowska. Molecular factors in endometrial cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(2): 190-192.
[11] G. Huizhen, H. Jiaming, C. Haitian, Y. Juan, L. Tianyu, S. Hongwei, W. Zilian, K. Peiqi. Overexpression of CUL4B is a novel predictor of prognosis for endometrial adenocarcinoma[J]. European Journal of Gynaecological Oncology, 2019, 40(2): 198-202.
[12] L. Bodnar, P. Knapp, J. Sznurkowski, R. Mądry, A. Gąsowska-Bodnar, M. Sikorska, A. Timorek, A. Ptak-Chmielewska, R. Jach, Polish Ovarian Cancer Group. Early initiation of chemotherapy after primary surgery as an adverse prognostic factor in patients with ovarian cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(2): 236-241.
[13] L. Baquedano, S. Castan, M. A. Ruiz-Conde, M. A. Martinez-Maestre, D. Judez, P. J. Coronado. Prognostic factors in high-grade endometrial cancer: does subtype matter?[J]. European Journal of Gynaecological Oncology, 2019, 40(2): 254-261.
[14] H. Cao, S. Yang, S. Xie, M. Xi. The association between p16INK4a and prognosis in endometrial carcinoma: a meta-analysis[J]. European Journal of Gynaecological Oncology, 2019, 40(2): 311-317.
[15] T. Oge, E. Uslu, S. Kabukcuoglu, O.T. Yalcin, S. Ozalp. The association of microcystic, elongated, and fragmented (MELF) invasion pattern in endometrial carcinomas with prognostic factors[J]. European Journal of Gynaecological Oncology, 2019, 40(1): 65-68.
No Suggested Reading articles found!